A-01 Registration at the conference venue Tuesday 15:00-18:30 |
A-02 Opening ceremony and welcome reception at the Old Fruitmarket on Candlerigs Tuesday 18:30-19:30 |
B-01 Registration at the conference venue Wednesday 08:00-08:45 |
B-02 Welcome and introduction Wednesday 08:45-09:00 |
B-03 Dyfrig Hughes Quantitative benefit-risk analysis based on linked PKPD and health outcome modelling Wednesday 09:00-09:40 |
B-06 Jonathan French Can methods based on existing models really aid decision making in non-small-cell lung cancer (NSCLC) trials? Wednesday 09:40-10:00 |
B-07 Jonas Bech Møller Optimizing clinical diabetes drug development – what is the recipe? Wednesday 10:00-10:20 |
B-08 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:20-11:45 |
B-09 Jim Riviere Food safety: the intersection of pharmacometrics and veterinary medicine Wednesday 11:45-12:25 |
B-10 Lunch Wednesday 12:25-13:50 |
B-11 George Gettinby Two models for the control of sea lice infections using chemical treatments and biological control on farmed salmon populations Wednesday 13:50-14:20 |
B-12 Dan Haydon From Epidemic to Elimination: Density-Vague Transmission and the Design of Mass Dog Vaccination Programs Wednesday 14:20-14:50 |
B-13 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 14:50-16:20 |
B-14 Wojciech Krzyzanski Physiologically Structured Population Model of Intracellular Hepatitis C Virus Dynamics Wednesday 16:20-16:40 |
B-15 Martin Bergstrand Modeling of the concentration-effect relationship for piperaquine in preventive treatment of malaria Wednesday 16:40-17:00 |
B-16 Matt Hutmacher A Visual Predictive Check for the Evaluation of the Hazard Function in Time-to-Event Analyses Wednesday 17:00-17:20 |
B-17 Celine M. Laffont Non-inferiority clinical trials: a multivariate test for multivariate PD Wednesday 17:20-17:40 |
C-01 Abhishek Gulati Simplification of a multi-scale systems coagulation model with an application to modelling PKPD data Thursday 08:45-09:10 |
C-19 Nelleke Snelder Mechanism-based PKPD modeling of cardiovascular effects in conscious rats - an application to fingolimod Thursday 09:10-09:35 |
C-20 Nadia Terranova Mathematical models of tumor growth inhibition in xenograft mice after administration of anticancer agents given in combination Thursday 09:35-10:00 |
C-21 Presentation of Lewis Sheiner student session awards Thursday 10:00-10:05 |
C-22 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 10:05-11:35 |
C-23 James Lu Application of a mechanistic, systems model of lipoprotein metabolism and kinetics to target selection and biomarker identification in the reverse cholesterol transport (RCT) pathway Thursday 11:35-11:55 |
C-24 Rollo Hoare A Novel Mechanistic Model for CD4 Lymphocyte Reconstitution Following Paediatric Haematopoietic Stem Cell Transplantation Thursday 11:55-12:15 |
C-25 Huub Jan Kleijn Utilization of Tracer Kinetic Data in Endogenous Pathway Modeling: Example from Alzheimer’s Disease Thursday 12:15-12:35 |
C-26 Lunch Thursday 12:35-14:05 |
C-27 Justin Wilkins Reproducible pharmacometrics Thursday 14:05-14:35 |
C-28 Nick Holford MDL - The DDMoRe Modelling Description Language Thursday 14:35-14:55 |
C-29 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 14:55-16:20 |
C-30 Vittal Shivva Identifiability of Population Pharmacokinetic-Pharmacodynamic Models Thursday 16:20-16:40 |
C-31 Leonid Gibiansky Methods to Detect Non-Compliance and Minimize its Impact on Population PK Parameter Estimates Thursday 16:40-17:00 |
C-32 Julie Bertrand Penalized regression implementation within the SAEM algorithm to advance high-throughput personalized drug therapy Thursday 17:00-17:20 |
C-33 Social event at The Arches, 253 Argyle Street Thursday Evening 19:00 |
D-01 Shelby Wilson Modeling the synergism between the anti-angiogenic drug sunitinib and irinotecan in xenografted mice Friday 09:00-09:20 |
D-35 S. Y. Amy Cheung Using a model based approach to inform dose escalation in a Ph I Study by combining emerging clinical and prior preclinical information: an example in oncology Friday 09:20-09:40 |
D-36 Sonya Chapman Tumour growth inhibition modelling and prediction of overall survival in patients with metastatic breast cancer treated with paclitaxel alone or in combination with gemcitabine Friday 09:40-10:00 |
D-37 Preview of PAGE2014 Friday 10:00-10:10 |
D-38 Coffee break Friday 10:10-10:50 |
D-39 Chuanpu Hu Latent variable indirect response modeling of continuous and categorical clinical endpoints Friday 10:50-11:10 |
D-40 Anne-Gaelle Dosne Application of Sampling Importance Resampling to estimate parameter uncertainty distributions Friday 11:10-11:30 |
D-41 Hoai-Thu Thai Bootstrap methods for estimating uncertainty of parameters in mixed-effects models Friday 11:30-11:50 |
D-42 Celia Barthelemy New methods for complex models defined by a large number of ODEs. Application to a Glucose/Insulin model Friday 11:50-12:10 |
D-43 Closing remarks Friday 12:10-12:20 |
D-44 Audience input for potential PAGE2014 topics Friday 12:20-12:40 |
I-01 Andrijana Radivojevic Enhancing population PK modeling efficiency using an integrated workflow Wednesday 10:05-11:40 |
I-02 Gauri Rao A Proposed Adaptive Feedback Control (AFC) Algorithm for Linezolid (L) based on Population Pharmacokinetics (PK)/Pharmacodynamics (PD)/Toxicodynamics(TD) Wednesday 10:05-11:40 |
I-03 Sylvie Retout A drug development tool for trial simulation in prodromal Alzheimer’s patient using the Clinical Dementia Rating scale Sum of Boxes score (CDR-SOB). Wednesday 10:05-11:40 |
I-04 Philippe Jacqmin Constructing the disease trajectory of CDR-SOB in Alzheimer’s disease progression modelling Wednesday 10:05-11:40 |
I-05 Rachel Rose Application of a Physiologically Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model to Investigate the Effect of OATP1B1 Genotypes on the Cholesterol Synthesis Inhibitory Effect of Rosuvastatin Wednesday 10:05-11:40 |
I-06 Elisabeth Rouits Population pharmacokinetic model for Debio 1143, a novel antagonist of IAPs in cancer treatment Wednesday 10:05-11:40 |
I-07 Alberto Russu Second-order indirect response modelling of complex biomarker dynamics Wednesday 10:05-11:40 |
I-08 Teijo Saari Pharmacokinetics of free hydromorphone concentrations in patients after cardiac surgery Wednesday 10:05-11:40 |
I-09 Tarjinder Sahota Real data comparisons of NONMEM 7.2 estimation methods with parallel processing on target-mediated drug disposition models Wednesday 10:05-11:40 |
I-10 Maria Luisa Sardu Tumour Growth Inhibition In Preclinical Animal Studies: Steady-State Analysis Of Biomarker-Driven Models. Wednesday 10:05-11:40 |
I-11 Emilie Schindler PKPD-Modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size following axitinib treatment in metastatic renal cell carcinoma (mRCC) patients Wednesday 10:05-11:40 |
I-12 Alessandro Schipani Population pharmacokinetic of rifampicine in Malawian children. Wednesday 10:05-11:40 |
I-13 Henning Schmidt The “SBPOP Package”: Efficient Support for Model Based Drug Development – From Mechanistic Models to Complex Trial Simulation Wednesday 10:05-11:40 |
I-14 Stephan Schmidt Mechanistic Prediction of Acetaminophen Metabolism and Pharmacokinetics in Children using a Physiologically-Based Pharmacokinetic (PBPK) Modeling Approach Wednesday 10:05-11:40 |
I-15 Rik Schoemaker Scaling brivaracetam pharmacokinetic parameters from adult to pediatric epilepsy patients Wednesday 10:05-11:40 |
I-16 Seonghae Yoon Population pharmacokinetic analysis of two different formulations of tacrolimus in stable pediatric kidney transplant recipients Wednesday 10:05-11:40 |
I-17 Catherine Sherwin Dense Data - Methods to Handle Massive Data Sets without Compromise Wednesday 10:05-11:40 |
I-18 Giovanni Smania Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation Wednesday 10:05-11:40 |
I-19 Alexander Solms Translating physiologically based Parameterization and Inter-Individual Variability into the Analysis of Population Pharmacokinetics Wednesday 10:05-11:40 |
I-20 Hankil Son A conditional repeated time-to-event analysis of onset and retention times of sildenafil erectile response Wednesday 10:05-11:40 |
I-21 Heiner Speth Referenced Visual Predictive Check (rVPC) Wednesday 10:05-11:40 |
I-22 Michael Spigarelli Title: Rapid Repeat Dosing of Zolpidem - Apparent Kinetic Change Between Doses Wednesday 10:05-11:40 |
I-23 Christine Staatz Dosage individulisation of tacroliums in adult kidney transplant recipients Wednesday 10:05-11:40 |
I-24 Gabriel Stillemans A generic population pharmacokinetic model for tacrolimus in pediatric and adult kidney and liver allograft recipients Wednesday 10:05-11:40 |
I-25 Elisabet Størset Predicting tacrolimus doses early after kidney transplantation - superiority of theory based models Wednesday 10:05-11:40 |
I-26 Fran Stringer A Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data in Japanese Type 2 Diabetes Patients Wednesday 10:05-11:40 |
I-27 Eric Strömberg FIM approximation, spreading of optimal sampling times and their effect on parameter bias and precision. Wednesday 10:05-11:40 |
I-28 Herbert Struemper Population pharmacokinetics of belimumab in systemic lupus erythematosus: insights for monoclonal antibody covariate modeling from a large data set Wednesday 10:05-11:40 |
I-29 Elin Svensson Individualization of fixed-dose combination (FDC) regimens - methodology and application to pediatric tuberculosis Wednesday 10:05-11:40 |
I-30 Eva Sverrisdottir Modelling analgesia-concentration relationships for morphine to evaluate experimental pain models Wednesday 10:05-11:40 |
I-31 Maciej Swat PharmML – An Exchange Standard for Models in Pharmacometrics Wednesday 10:05-11:40 |
I-32 Amit Taneja From Behaviour to Target: Evaluating the putative correlation between clinical pain scales and biomarkers. Wednesday 10:05-11:40 |
I-33 Joel Tarning The population pharmacokinetic and pharmacodynamic properties of intramuscular artesunate and quinine in Tanzanian children with severe falciparum malaria; implications for a practical dosing regimen. Wednesday 10:05-11:40 |
I-34 David Ternant Adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis Wednesday 10:05-11:40 |
I-35 Adrien Tessier High-throughput genetic screening and pharmacokinetic population modeling in drug development Wednesday 10:05-11:40 |
I-36 Iñaki F. Trocóniz Modelling and simulation applied to personalised medicine Wednesday 10:05-11:40 |
I-37 Nikolaos Tsamandouras A mechanistic population pharmacokinetic model for simvastatin and its active metabolite simvastatin acid Wednesday 10:05-11:40 |
I-38 Sebastian Ueckert AD i.d.e.a. – Alzheimer’s Disease integrated dynamic electronic assessment of Cognition Wednesday 10:05-11:40 |
I-39 Wanchana Ungphakorn Development of a Physiologically Based Pharmacokinetic Model for Children with Severe Malnutrition Wednesday 10:05-11:40 |
I-40 Elodie Valade Population Pharmacokinetics of Emtricitabine in HIV-1-infected Patients Wednesday 10:05-11:40 |
I-41 Georgia Valsami Population exchangeability in Bayesian dose individualization of oral Busulfan Wednesday 10:05-11:40 |
I-42 Sven van Dijkman Predicting antiepileptic drug concentrations for combination therapy in children with epilepsy. Wednesday 10:05-11:40 |
I-43 Coen van Hasselt Design and analysis of studies investigating the pharmacokinetics of anti-cancer agents during pregnancy Wednesday 10:05-11:40 |
I-44 Anne van Rongen Population pharmacokinetic model characterising the influence of circadian rhythm on the pharmacokinetics of oral and intravenous midazolam in healthy volunteers Wednesday 10:05-11:40 |
I-45 Marc Vandemeulebroecke Literature databases: integrating information on diseases and their treatments. Wednesday 10:05-11:40 |
I-46 Nieves Velez de Mendizabal A Population PK Model For Citalopram And Its Major Metabolite, N-desmethyl Citalopram, In Rats Wednesday 10:05-11:40 |
I-47 An Vermeulen Population Pharmacokinetic Analysis of Canagliflozin, an Orally Active Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) Wednesday 10:05-11:40 |
I-48 Marie Vigan Modelling the evolution of two biomarkers in Gaucher patients receiving enzyme replacement therapy. Wednesday 10:05-11:40 |
I-49 Paul Vigneaux Extending Monolix to use models with Partial Differential Equations Wednesday 10:05-11:40 |
I-50 Winnie Vogt Paediatric PBPK drug-disease modelling and simulation towards optimisation of drug therapy: an example of milrinone for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery Wednesday 10:05-11:40 |
I-51 Max von Kleist Systems Pharmacology of Chain-Terminating Nucleoside Analogs Wednesday 10:05-11:40 |
I-52 Camille Vong Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin. Wednesday 10:05-11:40 |
I-53 Katarina Vučićević Total plasma protein and haematocrit influence on tacrolimus clearance in kidney transplant patients - population pharmacokinetic approach Wednesday 10:05-11:40 |
I-54 Bing Wang Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and asthma patients Wednesday 10:05-11:40 |
I-55 Jixian Wang Design and analysis of randomized concentration controlled Wednesday 10:05-11:40 |
I-56 Franziska Weber A linear mixed effect model describing the expression of peroxisomal ABCD transporters in CD34+ stem cell-derived immune cells of X-linked Adrenoleukodystrophy and control populations Wednesday 10:05-11:40 |
I-57 Sebastian Weber PK/PD assessment of tacrolimus nephrotoxicity in liver transplantation Wednesday 10:05-11:40 |
I-58 Mélanie Wilbaux A drug-independent model predicting Progression-Free Survival to support early drug development in recurrent ovarian cancer Wednesday 10:05-11:40 |
I-59 Dan Wright Bayesian dose individualisation provides good control of warfarin dosing. Wednesday 10:05-11:40 |
I-60 Klintean Wunnapuk Population analysis of paraquat toxicokinetics in poisoning patients Wednesday 10:05-11:40 |
I-61 Rujia Xie Population PK-QT analysis across Phase I studies for a p38 mitogen activated protein kinase inhibitor – PH-797804 Wednesday 10:05-11:40 |
I-62 Shuying Yang First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis Wednesday 10:05-11:40 |
I-63 Jiansong Yang Practical diagnostic plots in aiding model selection among the general model for target-mediated drug disposition (TMDD) and its approximations Wednesday 10:05-11:40 |
I-64 Rui Zhu Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy Wednesday 10:05-11:40 |
II-01 Thomas Dorlo Miltefosine treatment failure in visceral leishmaniasis in Nepal is associated with low drug exposure Wednesday 14:50-16:20 |
II-02 Anne Dubois Using Optimal Design Methods to Help the Design of a Paediatric Pharmacokinetic Study Wednesday 14:50-16:20 |
II-03 Cyrielle Dumont Influence of the ratio of the sample sizes between the two stages of an adaptive design: application for a population pharmacokinetic study in children Wednesday 14:50-16:20 |
II-04 Thomas Dumortier Using a model-based approach to address FDA’s midcycle review concerns by demonstrating the contribution of everolimus to the efficacy of its combination with low exposure tacrolimus in liver transplantation Wednesday 14:50-16:20 |
II-05 Mike Dunlavey Support in PML for Absorption Time Lag via Transit Compartments Wednesday 14:50-16:20 |
II-06 Charles Ernest Optimal design of a dichotomous Markov-chain mixed-effect sleep model Wednesday 14:50-16:20 |
II-07 Christine Falcoz PKPD Modeling of Imeglimin Phase IIa Monotherapy Studies in Type 2 Diabetes Mellitus (T2DM) Wednesday 14:50-16:20 |
II-08 Floris Fauchet Population pharmacokinetics of Zidovudine and its metabolite in HIV-1 infected children: Evaluation doses recommended Wednesday 14:50-16:20 |
II-09 Eric Fernandez drugCARD: a database of anti-cancer treatment regimens and drug combinations Wednesday 14:50-16:20 |
II-10 Martin Fink Animal Health Modeling & Simulation Society (AHM&S): A new society promoting model-based approaches for a better integration and understanding of quantitative pharmacology in Veterinary Sciences Wednesday 14:50-16:20 |
II-11 Sylvain Fouliard Semi-mechanistic population PKPD modelling of a surrogate biomarker Wednesday 14:50-16:20 |
II-12 Nicolas Frances A semi-physiologic mathematical model describing pharmacokinetic profile of an IgG monoclonal antibody mAbX after IV and SC administration in human FcRn transgenic mice. Wednesday 14:50-16:20 |
II-13 Chris Franklin : Introducing DDMoRe’s framework within an existing enterprise modelling and simulation environment. Wednesday 14:50-16:20 |
II-14 Ludivine Fronton A Novel PBPK Approach for mAbs and its Implications in the Interpretation of Classical Compartment Models Wednesday 14:50-16:20 |
II-15 Aline Fuchs Population pharmacokinetic study of gentamicin: a retrospective analysis in a large cohort of neonate patients Wednesday 14:50-16:20 |
II-16 Aurelie Gautier Pharmacokinetics of Canakinumab and pharmacodynamics of IL-1β binding in cryopyrin associated periodic fever, a step towards personalized medicine Wednesday 14:50-16:20 |
II-17 Ronette Gehring A dynamically integrative PKPD model to predict the efficacy of marbofloxacin treatment regimens for bovine Mannheimia hemolytica infection Wednesday 14:50-16:20 |
II-18 Peter Gennemark Incorporating model structure uncertainty in model-based drug discovery Wednesday 14:50-16:20 |
II-19 Eva Germovsek Age-Corrected Creatinine is a Significant Covariate for Gentamicin Clearance in Neonates Wednesday 14:50-16:20 |
II-20 TJ Carrothers Comparison of Analysis Methods for Population Exposure-Response in Thorough QT Studies Wednesday 14:50-16:20 |
II-21 Parviz Ghahramani Population PKPD Modeling of Milnacipran Effect on Blood Pressure and Heart Rate Over 24-Hour Period Using Ambulatory Blood Pressure Monitoring in Normotensive and Hypertensive Patients With Fibromyalgia Wednesday 14:50-16:20 |
II-22 Ekaterina Gibiansky Immunogenicity in PK of Monoclonal Antibodies: Detection and Unbiased Estimation of Model Parameters Wednesday 14:50-16:20 |
II-23 Leonid Gibiansky Monoclonal Antibody-Drug Conjugates (ADC): Simplification of Equations and Model-Independent Assessment of Deconjugation Rate Wednesday 14:50-16:20 |
II-24 Pascal Girard Tumor size model and survival analysis of cetuximab and various cytotoxics in patients treated for metastatic colorectal cancer Wednesday 14:50-16:20 |
II-25 Sophie Gisbert Is it possible to use the plasma and urine pharmacokinetics of a monoclonal antibody (mAb) as an early marker of efficacy in membranous nephropathy (MN)? Wednesday 14:50-16:20 |
II-26 Timothy Goggin Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. Wednesday 14:50-16:20 |
II-27 Roberto Gomeni Implementing adaptive study design in clinical trials for psychiatric disorders using band-pass filtering approach Wednesday 14:50-16:20 |
II-28 José David Gómez-Mantilla Tailor-made dissolution profile comparisons using in vitro-in vivo correlation models. Wednesday 14:50-16:20 |
II-29 Ignacio Gonzalez-Garcia Simultaneous Modelling Of Fexofenadine In In Vitro Cell Culture And In Situ Experiments Wednesday 14:50-16:20 |
II-30 Sathej Gopalakrishnan Towards assessing therapy failure in HIV disease: estimating in vivo fitness characteristics of viral mutants by an integrated statistical-mechanistic approach Wednesday 14:50-16:20 |
II-31 Verena Gotta Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients Wednesday 14:50-16:20 |
II-32 Bruce Green Clinical Application of a K-PD Warfarin Model for Bayesian Dose Individualisation in Primary Care Wednesday 14:50-16:20 |
II-33 Zheng Guan The influence of variability in serum prednisolone pharmacokinetics on clinical outcome in children with nephrotic syndrome, based on salivary sampling combined with translational modeling and simulation approaches from healthy adult volunteers Wednesday 14:50-16:20 |
II-34 Monia Guidi Impacts of environmental, clinical and genetic factors on the response to vitamin D supplementation in HIV-positive patients Wednesday 14:50-16:20 |
II-35 Vanessa Guy-Viterbo Tacrolimus in pediatric liver recipients: population pharmacokinetic analysis during the first year post transplantation Wednesday 14:50-16:20 |
II-36 Chihiro Hasegawa Modeling & simulation of ONO-4641, a sphingosine 1-phosphate receptor modulator, to support dose selection with phase 1 data Wednesday 14:50-16:20 |
II-37 Michael Heathman The Application of Drug-Disease and Clinical Utility Models in the Design of an Adaptive Seamless Phase 2/3 Study Wednesday 14:50-16:20 |
II-38 Emilie Hénin Optimization of sorafenib dosing regimen using the concept of utility Wednesday 14:50-16:20 |
II-39 Eef Hoeben Prediction of Serotonin 2A Receptor (5-HT2AR) Occupancy in Man From Nonclinical Pharmacology Data. Exposure vs. 5-HT2AR Occupancy Modeling Used to Help Design a Positron Emission Tomography (PET) Study in Healthy Male Subjects. Wednesday 14:50-16:20 |
II-40 Taegon Hong Usefulness of Weibull-Type Absorption Model for the Population Pharmacokinetic Analysis of Pregabalin Wednesday 14:50-16:20 |
II-41 Andrew Hooker Platform for adaptive optimal design of nonlinear mixed effect models. Wednesday 14:50-16:20 |
II-42 Daniel Hovdal PKPD modelling of drug induced changes in thyroxine turnover in rat Wednesday 14:50-16:20 |
II-43 Hwi-yeol Yun Evaluation of FREM and FFEM including use of model linearization Wednesday 14:50-16:20 |
II-44 Ibrahim Ince Oral bioavailability of the CYP3A substrate midazolam across the human age range from preterm neonates to adults Wednesday 14:50-16:20 |
II-45 Lorenzo Ridolfi Predictive Modelling Environment - Infrastructure and functionality for pharmacometric activities in R&D Wednesday 14:50-16:20 |
II-46 Masoud Jamei Accounting for sex effect on QT prolongation by quinidine: A simulation study using PBPK linked with PD Wednesday 14:50-16:20 |
II-47 Alvaro Janda Application of optimal control methods to achieve multiple therapeutic objectives: Optimization of drug delivery in a mechanistic PK/PD system Wednesday 14:50-16:20 |
II-48 Nerea Jauregizar Pharmacokinetic/Pharmacodynamic modeling of time-kill curves for echinocandins against Candida. Wednesday 14:50-16:20 |
II-49 Roger Jelliffe Multiple Model Optimal Experimental Design for Pharmacokinetic Applications Wednesday 14:50-16:20 |
II-50 Sangil Jeon Population Pharmacokinetics of Piperacillin in Burn Patients Wednesday 14:50-16:20 |
II-51 Jeremie Guedj Modeling Early Viral Kinetics with Alisporivir: Interferon-free Treatment and SVR Predictions in HCV G2/3 patients Wednesday 14:50-16:20 |
II-52 Claire Johnston A population approach to investigating hepatic intrinsic clearance in old age: Pharmacokinetics of paracetamol and its metabolites Wednesday 14:50-16:20 |
II-53 Niclas Jonsson Population PKPD analysis of weekly pain scores after intravenously administered tanezumab, based on pooled Phase 3 data in patients with osteoarthritis of the knee or hip Wednesday 14:50-16:20 |
II-54 Marija Jovanovic Effect of Carbamazepine Daily Dose on Topiramate Clearance - Population Modelling Approach Wednesday 14:50-16:20 |
II-55 Rasmus Juul Kildemoes Pharmacokinetic modelling as a tool to assess transporter involvement in vigabatrin absorption Wednesday 14:50-16:20 |
II-56 Matts Kågedal A modelling approach allowing different nonspecific uptake in the reference region and regions of interest – Opening up the possibility to use white matter as a reference region in PET occupancy studies. Wednesday 14:50-16:20 |
II-57 Ana Novakovic Application of Item Response Theory to EDSS Modeling in Multiple Sclerosis Wednesday 14:50-16:20 |
II-58 Takayuki Katsube Pharmacokinetic/pharmacodynamic modeling and simulation for concentration-dependent bactericidal activity of a bicyclolide, modithromycin Wednesday 14:50-16:20 |
II-59 Irene-Ariadne Kechagia Population pharmacokinetic analysis of colistin after administration of inhaled colistin methanesulfonate. Wednesday 14:50-16:20 |
II-60 Ron Keizer cPirana: command-line user interface for NONMEM and PsN Wednesday 14:50-16:20 |
II-61 Frank Kloprogge Population pharmacokinetics and pharmacodynamics of lumefantrine in pregnant women with uncomplicated P. falciparum malaria. Wednesday 14:50-16:20 |
II-62 Gilbert Koch Solution and implementation of distributed lifespan models Wednesday 14:50-16:20 |
II-64 Julia Korell Gaining insight into red blood cell destruction mechanisms using a previously developed semi-mechanistic model Wednesday 14:50-16:20 |
III-01 Stefanie Kraff Excel®-Based Tools for Pharmacokinetically Guided Dose Adjustment of Paclitaxel and Docetaxel Thursday 10:05-11:35 |
III-02 Andreas Krause Modeling the two peak phenomenon in pharmacokinetics using a gut passage model with two absorption sites Thursday 10:05-11:35 |
III-03 Elke Krekels Item response theory for the analysis of the placebo effect in Phase 3 studies of schizophrenia Thursday 10:05-11:35 |
III-04 Anders Kristoffersson Inter Occasion Variability (IOV) in Individual Optimal Design (OD) Thursday 10:05-11:35 |
III-05 Cédric Laouenan Modelling early viral hepatitis C kinetics in compensated cirrhotic treatment-experienced patients treated with triple therapy including telaprevir or boceprevir Thursday 10:05-11:35 |
III-06 Anna Largajolli An integrated glucose-insulin minimal model for IVGTT Thursday 10:05-11:35 |
III-07 Robert Leary A Fast Bootstrap Method Using EM Posteriors Thursday 10:05-11:35 |
III-08 Donghwan Lee Development of a Disease Progression Model in Korean Patients with Type 2 Diabetes Mellitus(T2DM) Thursday 10:05-11:35 |
III-09 Joomi Lee Population pharmacokinetics of prothionamide in Korean tuberculosis patients Thursday 10:05-11:35 |
III-10 Junghoon Lee Modeling Targeted Therapies in Oncology: Incorporation of Cell-cycle into a Tumor Growth Inhibition Model Thursday 10:05-11:35 |
III-11 Tarek Leil PK-PD Modeling using 4β-Hydroxycholesterol to Predict CYP3A Mediated Drug Interactions Thursday 10:05-11:35 |
III-12 Annabelle Lemenuel Diot How to improve the prediction of Sustained Virologic Response (SVR) for Hepatitis C patients using early Viral Load (VL) Information Thursday 10:05-11:35 |
III-13 Joanna Lewis A homeostatic model for CD4 count recovery in HIV-infected children Thursday 10:05-11:35 |
III-14 Yan Li Modeling and Simulation to Probe the Likely Difference in Pharmacokinetic Disposition of R- and S-Enantiomers Justifying the Development of Racemate Pomalidomide Thursday 10:05-11:35 |
III-15 Lia Liefaard Predicting levels of pharmacological response in long-term patient trials based on short-term dosing PK and biomarker data from healthy subjects Thursday 10:05-11:35 |
III-16 Karl-Heinz Liesenfeld Pharmacometric Characterization of the Elimination of Dabigatran by Haemodialysis Thursday 10:05-11:35 |
III-17 Otilia Lillin Model-based QTc interval risk assessment in Phase 1 studies and its impact on the drug development trajectory Thursday 10:05-11:35 |
III-18 Hyeong-Seok Lim Pharmacokinetics of S-1, an Oral 5-Fluorouracil Agent in Patients with Gastric Surgery Thursday 10:05-11:35 |
III-19 Andreas Lindauer Comparison of NONMEM Estimation Methods in the Application of a Markov-Model for Analyzing Sleep Data Thursday 10:05-11:35 |
III-20 Jesmin Lohy Das Simulations to investigate new Intermittent Preventive Therapy Dosing Regimens for Dihydroartemisinin-Piperaquine Thursday 10:05-11:35 |
III-21 Dan Lu Semi-mechanistic Multiple-analyte Population Model of Antibody-drug-conjugate Pharmacokinetics Thursday 10:05-11:35 |
III-22 Viera Lukacova Physiologically Based Pharmacokinetic (PBPK) Modeling of Amoxicillin in Neonates and Infants Thursday 10:05-11:35 |
III-23 Panos Macheras On the Properties of a Two-Stage Design for Bioequivalence Studies Thursday 10:05-11:35 |
III-24 Merran Macpherson Using modelling and simulation to evaluate potential drug repositioning to a new therapy area Thursday 10:05-11:35 |
III-25 Paolo Magni A PK-PD model of tumor growth after administration of an anti-angiogenic agent given alone or in combination therapies in xenograft mice Thursday 10:05-11:35 |
III-26 Mathilde Marchand Population Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Daratumumab in Multiple Myeloma Patients Thursday 10:05-11:35 |
III-27 Eleonora Marostica Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies Thursday 10:05-11:35 |
III-28 Hafedh Marouani Dosage regimen individualization of the once-daily amikacin treatment by using kinetics nomograms. Thursday 10:05-11:35 |
III-29 Amelie Marsot Population pharmacokinetics of baclofen in alcohol dependent patients Thursday 10:05-11:35 |
III-30 María Isabel Mas Fuster Stochastic Simulations Assist to Select the Intravenous Digoxin Dosing Protocol in Elderly Patients in Acute Atrial Fibrillation Thursday 10:05-11:35 |
III-31 Pauline Mazzocco Modeling tumor dynamics and overall survival in patients with low-grade gliomas treated with temozolomide. Thursday 10:05-11:35 |
III-32 Litaty Céphanoée Mbatchi A PK-PGx study of irinotecan: influence of genetic polymorphisms of xenoreceptors CAR (NR1I3) and PXR (NR1I2) on PK parameters Thursday 10:05-11:35 |
III-33 Sarah McLeay Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastro-esophageal reflux disease in children aged 1-11 years Thursday 10:05-11:35 |
III-34 Christophe Meille Modeling of Erlotinib Effect on Cell Growth Measured by in vitro Impedance-based Real-Time Cell Analysis Thursday 10:05-11:35 |
III-35 Olesya Melnichenko Characterizing the dose-efficacy relationship for anti-cancer drugs using longitudinal solid tumor modeling Thursday 10:05-11:35 |
III-36 Enrica Mezzalana A Target-Mediated Drug Disposition model integrated with a T lymphocyte pharmacodynamic model for Otelixizumab. Thursday 10:05-11:35 |
III-37 Iris Minichmayr A Microdialysate-based Integrated Model with Nonlinear Elimination for Determining Plasma and Tissue Pharmacokinetics of Linezolid in Four Distinct Populations Thursday 10:05-11:35 |
III-38 Jonathan Mochel Chronobiology of the Renin-Angiotensin-Aldosterone System (RAAS) in Dogs: Relation to Blood Pressure and Renal Physiology Thursday 10:05-11:35 |
III-39 Dirk Jan Moes Evaluating the effect of CYP3A4 and CYP3A5 polymorphisms on cyclosporine, everolimus and tacrolimus pharmacokinetics in renal transplantation patients. Thursday 10:05-11:35 |
III-40 John Mondick Mixed Effects Modeling to Quantify the Effect of Empagliflozin Exposure on the Renal Glucose Threshold in Patients with Type 2 Diabetes Mellitus Thursday 10:05-11:35 |
III-41 Morris Muliaditan Model-based evaluation of iron overload in patients affected by transfusion dependent diseases Thursday 10:05-11:35 |
III-42 Flora Musuamba-Tshinanu Modelling of disease progression and drug effects in preclinical models of neuropathic pain Thursday 10:05-11:35 |
III-43 Kiyohiko Nakai Urinary C-terminal Telopeptide of Type-I Collagen Concentration (uCTx) as a Possible Biomarker for Osteoporosis Treatment; A Direct Comparison of the Modeling and Simulation (M&S) Data and those Actually Obtained in Japanese Patients with Osteoporosis Following a Three-year-treatment with Ibandronic Acid (IBN) Thursday 10:05-11:35 |
III-44 Thu Thuy Nguyen Mechanistic Model to Characterize and Predict Fecal Excretion of Ciprofloxacin Resistant Enterobacteria with Various Dosage Regimens Thursday 10:05-11:35 |
III-45 Tram Nguyen Influence of a priori information, designs and undetectable data on individual parameters estimation and prediction of hepatitis C treatment outcome Thursday 10:05-11:35 |
III-46 Xavier Nicolas Steady-state achievement and accumulation for a compound with bi-phasic disposition and long terminal half-life, estimation by different techniques Thursday 10:05-11:35 |
III-47 Ronald Niebecker Are datasets for NLME models large enough for a bootstrap to provide reliable parameter uncertainty distributions? Thursday 10:05-11:35 |
III-48 Lisa O'Brien Implementation of a Global NONMEM Modeling Environment Thursday 10:05-11:35 |
III-49 Kayode Ogungbenro A physiological based pharmacokinetic model for low dose methotrexate in humans Thursday 10:05-11:35 |
III-50 Jaeseong Oh A Population Pharmacokinetic-Pharmacodynamic Analysis of Fimasartan in Patients with Mild to Moderate Essential Hypertension Thursday 10:05-11:35 |
III-51 Fredrik Öhrn Longitudinal Modelling of FEV1 Effect of Bronchodilators Thursday 10:05-11:35 |
III-52 Andrés Olivares-Morales Qualitative prediction of human oral bioavailability from animal oral bioavailability data employing ROC analysis Thursday 10:05-11:35 |
III-53 Erik Olofsen Simultaneous stochastic modeling of pharmacokinetic and pharmacodynamic data with noncoinciding sampling times Thursday 10:05-11:35 |
III-54 Sean Oosterholt PKPD modelling of PGE2 inhibition and dose selection of a novel COX-2 inhibitor in humans. Thursday 10:05-11:35 |
III-55 Ignacio Ortega Application of allometric techniques to predict F10503LO1 PK parameters in human Thursday 10:05-11:35 |
III-56 Jeongki Paek Population pharmacokinetic model of sildenafil describing first-pass effect to its metabolite Thursday 10:05-11:35 |
III-57 Sung Min Park Population pharmacokinetic/pharmacodynamic modeling for transformed binary effect data of triflusal in healthy Korean male volunteers Thursday 10:05-11:35 |
III-58 Zinnia Parra-Guillen Population semi-mechanistic modelling of tumour response elicited by Immune-stimulatory based therapeutics in mice Thursday 10:05-11:35 |
III-59 Ines Paule Population pharmacokinetics of an experimental drug’s oral modified release formulation in healthy volunteers, quantification of sensitivity to types and timings of meals. Thursday 10:05-11:35 |
III-60 Sophie Peigné Paediatric Pharmacokinetic methodologies: Evaluation and comparison Thursday 10:05-11:35 |
III-61 Nathalie Perdaems A semi-mechanistic PBPK model to predict blood, cerebrospinal fluid and brain concentrations of a compound in mouse, rat, monkey and human. Thursday 10:05-11:35 |
III-62 Chiara Piana Optimal sampling and model-based dosing algorithm for busulfan in bone marrow transplantation patients. Thursday 10:05-11:35 |
III-63 Sebastian Polak Pharmacokinetic (PK) and pharmacodynamic (PD) implications of diurnal variation of gastric emptying and small intestinal transit time for quinidine: A mechanistic simulation. Thursday 10:05-11:35 |
III-64 Angelica Quartino Evaluation of Tumor Size Metrics to Predict Survival in Advanced Gastric Cancer Thursday 10:05-11:35 |
IV-01 Khaled Abduljalil Prediction of Tolerance to Caffeine Pressor Effect during Pregnancy using Physiologically Based PK-PD Modelling Thursday 14:55-16:20 |
IV-02 Rick Admiraal Exposure to the biological anti-thymocyte globulin (ATG) in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards individualized dosing to improve survival Thursday 14:55-16:20 |
IV-03 Wafa Alfwzan Mathematical Modelling of the Spread of Hepatitis C among Drug Users, effects of heterogeneity. Thursday 14:55-16:20 |
IV-04 Sarah Alghanem Comparison of NONMEM and Pmetrics Analysis for Aminoglycosides in Adult Patients with Cystic Fibrosis Thursday 14:55-16:20 |
IV-05 Nidal Huniti A Nonlinear Mixed Effect Model to Describe Placebo Response in Children and Adolescents with Major Depressive Disorder Thursday 14:55-16:20 |
IV-06 Hesham Al-Sallami Evaluation of a Bayesian dose-individualisation method for enoxaparin Thursday 14:55-16:20 |
IV-07 Oskar Alskär Modelling of glucose absorption Thursday 14:55-16:20 |
IV-08 Helena Edlund Clinical relevance of albumin concentration in patients with Crohn’s disease treated with infliximab for recommendations on dosing regimen adjustments Thursday 14:55-16:20 |
IV-09 Franc Andreu Solduga Development of a Bayesian Estimator for Tacrolimus in Kidney Transplant Patients: A Population Pharmacokinetic approach. Thursday 14:55-16:20 |
IV-10 Yasunori Aoki PopED lite an easy to use experimental design software for preclinical studies Thursday 14:55-16:20 |
IV-11 Eduardo Asín-Prieto Population Pharmacokinetics of Cefuroxime in patients Undergoing Colorectal Surgery Thursday 14:55-16:20 |
IV-12 Ioanna Athanasiadou Simulation of the effect of hyperhydration on urine levels of recombinant human erythropoietin from a doping control point of view Thursday 14:55-16:20 |
IV-13 Guillaume Baneyx Modeling Erlotinib and Gefitinib in Vitro Penetration through Multiple Layers of Epidermoid and Colorectal Human Carcinoma Cells Thursday 14:55-16:20 |
IV-14 Aliénor Bergès Dose selection in Amyotrophic Lateral Sclerosis: PK/PD model using laser scanning cytometry data from muscle biopsies in a patient study Thursday 14:55-16:20 |
IV-15 Shanshan Bi Population Pharmacokinetic/Pharmacodynamic Modeling of Two Novel Neutral Endopeptidase Inhibitors in Healthy Subjects Thursday 14:55-16:20 |
IV-16 Bruno Bieth Population Pharmacokinetics of QVA149, the fixed dose combination of Indacaterol maleate and Glycopyrronium bromide in Chronic Obstructive Pulmonary Disease (COPD) patients Thursday 14:55-16:20 |
IV-17 Roberto Bizzotto Characterization of binding between OSM and mAb in RA patient study: an extension to TMDD models Thursday 14:55-16:20 |
IV-18 Marcus Björnsson Effect on bias in EC50 when using interval censoring or exact dropout times in the presence of informative dropout Thursday 14:55-16:20 |
IV-19 Karina Blei Mechanism of Action of Jellyfish (Carukia barnesi) Envenomation and its Cardiovascular Effects Resulting in Irukandji Syndrome Thursday 14:55-16:20 |
IV-20 Michael Block Predicting the antihypertensive effect of Candesartan-Nifedipine combinations based on public benchmarking data. Thursday 14:55-16:20 |
IV-21 Michael Block Physiologically-based PK/PD modeling for a dynamic cardiovascular system: structure and applications Thursday 14:55-16:20 |
IV-22 Irina Bondareva Population Modeling of the Time-dependent Carbamazepine (CBZ) Autoinduction Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Drug-naïve Adult Epileptic Patients Begun on CBZ-monotherapy Thursday 14:55-16:20 |
IV-23 Jens Markus Borghardt Characterisation of different absorption rate constants after inhalation of olodaterol Thursday 14:55-16:20 |
IV-25 Karl Brendel How to deal properly with change-point model in NONMEM? Thursday 14:55-16:20 |
IV-26 Frances Brightman Predicting Torsades de Pointes risk from data generated via high-throughput screening Thursday 14:55-16:20 |
IV-27 Margreke Brill Population pharmacokinetic model for protein binding and subcutaneous adipose tissue distribution of cefazolin in morbidly obese and non-obese patients Thursday 14:55-16:20 |
IV-28 Brigitte Brockhaus Semi-mechanistic model-based drug development of EMD 525797 (DI17E6), a novel anti-αv integrin monoclonal antibody Thursday 14:55-16:20 |
IV-30 Vincent Buchheit Data quality impacts on modeling results Thursday 14:55-16:20 |
IV-31 Núria Buil Bruna Modelling LDH dynamics to assess clinical response as an alternative to tumour size in SCLC patients Thursday 14:55-16:20 |
IV-33 Theresa Cain Prediction of Rosiglitazone compliance from last sampling information using Population based PBPK modelling and Bayes theorem: Comparison of prior distributions for compliance. Thursday 14:55-16:20 |
IV-34 Vicente G. Casabo Modification Of Non Sink Equation For Calculation The Permeability In Cell Monolayers Thursday 14:55-16:20 |
IV-35 Anne Chain Not-In-Trial Simulations: A tool for mitigating cardiovascular safety risks Thursday 14:55-16:20 |
IV-36 Kalayanee Chairat A population pharmacokinetics and pharmacodynamics of oseltamivir and oseltamivir carboxylate in adults and children infected with influenza virus A(H1N1)pdm09 Thursday 14:55-16:20 |
IV-37 Quentin Chalret du Rieu Hematological toxicity modelling of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor, in patients suffering from solid tumors or lymphoma: influence of the disease-progression on the drug-induced thrombocytopenia. Thursday 14:55-16:20 |
IV-38 Phylinda Chan Industry Experience in Establishing a Population Pharmacokinetic Analysis Guidance Thursday 14:55-16:20 |
IV-39 Pascal Chanu Simulation study for a potential sildenafil survival trial in adults with pulmonary arterial hypertension (PAH) using a time-varying exposure-hazard model developed from data in children Thursday 14:55-16:20 |
IV-40 Christophe Chassagnole Virtual Tumour Clinical: Literature example Thursday 14:55-16:20 |
IV-41 Chao Chen A mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition Thursday 14:55-16:20 |
IV-42 Chunli Chen Design optimization for characterization of rifampicin pharmacokinetics in mouse Thursday 14:55-16:20 |
IV-43 Nianhang Chen Comparison of Two Parallel Computing Methods (FPI versus MPI) in NONMEM 7.2 on complex popPK and popPK/PD Models Thursday 14:55-16:20 |
IV-44 Marylore Chenel Population Pharmacokinetic Modelling to Detect Potential Drug Interaction Using Sparse Sampling Data Thursday 14:55-16:20 |
IV-45 Jason Chittenden Practical Application of GPU Computing to Population PK Thursday 14:55-16:20 |
IV-46 Yu-Yuan Chiu Exposure-Efficacy Response Model of Lurasidone in Patients with Bipolar Depression Thursday 14:55-16:20 |
IV-47 Steve Choy Modelling the Effect of Very Low Calorie Diet on Weight and Fasting Plasma Glucose in Type 2 Diabetic Patients Thursday 14:55-16:20 |
IV-48 Oskar Clewe A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells Thursday 14:55-16:20 |
IV-49 Teresa Collins Performance of Sequential methods under Pre-clinical Study Conditions Thursday 14:55-16:20 |
IV-50 Francois Combes Influence of study design and associated shrinkage on power of the tests used for covariate detection in population pharmacokinetics Thursday 14:55-16:20 |
IV-51 Emmanuelle Comets Additional features and graphs in the new npde library for R Thursday 14:55-16:20 |
IV-52 Camille Couffignal Population pharmacokinetics of imipenem in intensive care unit patients with ventilated-associated pneumonia Thursday 14:55-16:20 |
IV-53 Damien Cronier PK/PD relationship of the monoclonal anti-BAFF antibody tabalumab in combination with bortezomib in patients with previously treated multiple myeloma: comparison of serum M-protein and serum Free Light Chains as predictor of Progression Free Survival Thursday 14:55-16:20 |
IV-54 Zeinab Daher Abdi Analysis of the relationship between Mycophenolic acid (MPA) exposure and anemia using three approaches: logistic regression based on Generalized Linear Mixed Models (GLMM) or on Generalized Estimating Equations (GEE) and Markov mixed-effects model. Thursday 14:55-16:20 |
IV-55 Elyes Dahmane Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients Thursday 14:55-16:20 |
IV-56 Adam Darwich A physiologically based pharmacokinetic model of oral drug bioavailability immediately post bariatric surgery Thursday 14:55-16:20 |
IV-57 Camila De Almeida Modelling Irinotecan PK, efficacy and toxicities pre-clinically Thursday 14:55-16:20 |
IV-58 Willem de Winter Population PK/PD analysis linking the direct acute effects of canagliflozin on renal glucose reabsorption to the overall effects of canagliflozin on long-term glucose control using HbA1c as the response marker from clinical studies Thursday 14:55-16:20 |
IV-59 Joost DeJongh A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. Thursday 14:55-16:20 |
IV-60 Paolo Denti A semi-physiological model for rifampicin and rifapentine CYP3A induction on midazolam pharmacokinetics. Thursday 14:55-16:20 |
IV-61 Cheikh Diack An indirect response model with modulated input rate to characterize the dynamics of Aβ-40 in cerebrospinal fluid Thursday 14:55-16:20 |
IV-62 Laura Dickinson Population Pharmacokinetics of Twice Daily Zidovudine (ZDV) in HIV-Infected Children and an Assessment of ZDV Exposure Following WHO Dosing Guidelines Thursday 14:55-16:20 |
IV-63 Christian Diedrich Using Bayesian-PBPK Modeling for Assessment of Inter-Individual Variability and Subgroup Stratification Thursday 14:55-16:20 |
IV-64 Christian Diestelhorst Population Pharmacokinetics of Intravenous Busulfan in Children: Revised Body Weight-Dependent NONMEM® Model to Optimize Dosing Thursday 14:55-16:20 |
IV-65 Aris Dokoumetzidis Bayesian parameter scan for determining bias in parameter estimates Thursday 14:55-16:20 |
S-01 Gregory Ferl Literate Programming Methods for Clinical M&S During entire meeting |
S-02 Bruce Green DoseMe - A Cross Platform Dose Individualised Program During entire meeting |
S-03 Roger Jelliffe The MM-USCPACK Pmetrics research software for nonparametric population PK/PD modeling, and the RightDose clinical software for individualizing maximally precise dosage regimens. During entire meeting |
S-04 Niclas Jonsson Reproducible pharmacometrics During entire meeting |